Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. From the ones listed this time, here's a few in our areas of research interest:
Charokopou M, McEwan P, Lister S, et. al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med. 2015 Mar 28. [Epub ahead of print] PubMed PMID: 25817050.
Joensuu JT, Huoponen S, Aaltonen KJ, et. al. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015 Mar 17;10(3):e0119683. eCollection 2015. PubMed PMID: 25781999.
Yeh JM, Hur C, Ward Z, et. al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. 2015 Mar 16. [Epub ahead of print] PubMed PMID: 25779597.
